The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of General Meeting

9 Jun 2020 16:45

RNS Number : 4154P
Mereo BioPharma Group plc
09 June 2020
 

 

Publication of Circular and Notice of General Meeting

 

London and Redwood City, Calif., June 9, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) announces that, further to the announcement regarding the completed Private Placement of $70 million (£56 million) (the "Fundraising") made on June 4, 2020, it has today published a circular (the "Circular") in connection with the Fundraising. 

 

The Circular contains a notice convening a General Meeting of the Company, at which certain resolutions in connection with the Fundraising will be put to shareholders. The meeting will be held at the 4th Floor, One Cavendish Place, London W1G 0QF, United Kingdom on 30 June 2020 at 11.00 a.m. (London time). In accordance with the UK Government's COVID-19 measures, ordinary shareholders are not expected to be allowed to attend the General Meeting in person, shareholders are therefore encouraged to submit their proxy vote electronically.

 

The Circular and the Notice of General Meeting will also be available for viewing on Mereo's website at https://www.mereobiopharma.com/ngm .

 

Terms used in this announcement shall have the same meaning as those used in the Circular.

 

About Mereo BioPharma

 

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with oncology and rare diseases. Mereo's strategy is to selectively acquire product candidates for oncology and rare diseases that have already received significant investment from pharmaceutical and large biotechnology companies and that have substantial preclinical, clinical and manufacturing data packages. Mereo's lead oncology product candidate, etigilimab, an anti-TIGIT, has completed a Phase 1a and Phase 1b for a range of solid tumor types and the second product candidate, navicixizumab, for ovarian cancer has been licensed to Oncologie Inc. for up to $300M in milestone payments. Mereo's lead rare disease product candidate, setrusumab, has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI") and a pivotal Phase 3 study design in paediatrics has been agreed with the FDA and EMA. Mereo's second lead product candidate, alvelestat, is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD"). Mereo plans to form a strategic partnership for setrusumab prior to initiation of the paediatric pivotal study. Following successful completion of Phase 2, Mereo is seeking partnerships for its two additional clinical-stage product candidates; acumapimod for the treatment of acute exacerbations of chronic obstructive pulmonary disease ("AECOPD"), leflutrozole for the treatment of infertility and hypogonadotropic hypogonadism ("HH") in obese men. 

 

Additional Information

 

The person responsible for arranging the release of this information on behalf of the Company is Charles Sermon, General Counsel.

 

Mereo BioPharma Contacts:

 

Mereo

+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer

 

 

 

Cantor Fitzgerald Europe (Nominated Adviser and Broker to Mereo)

+44 (0)20 7894 7000

Phil Davies

 

Will Goode

 

 

 

Burns McClellan (US Public Relations Adviser to Mereo)

+01 (0) 212 213 0006

Lisa Burns

 

Steve Klass

 

 

 

FTI Consulting (UK Public Relations Adviser to Mereo)

 +44 (0)20 3727 1000

Simon Conway

 

Ciara Martin

 

 

 

Investors

investors@mereobiopharma.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOGFLFFIRIIAIII
Date   Source Headline
3rd Nov 20052:53 pmRNSNotice of Interim Results
31st Oct 200510:54 amRNSBoard Changes
19th Oct 20057:00 amRNSAgreement extension
9th Sep 20057:00 amRNSDirector/PDMR Shareholding
6th Sep 200511:55 amRNSResult of AGM
2nd Sep 20059:39 amRNSHolding(s) in Company
19th Aug 200510:40 amRNSAcquisition
3rd Aug 20057:02 amRNSAcquisition
2nd Aug 20059:52 amRNSUpdate
20th Jul 20057:01 amRNSCollection in Flagship Stores
22nd Jun 20057:00 amRNSHolding(s) in Company
8th Jun 20057:00 amRNSFinal Results
12th May 200511:48 amRNSBlocklisting application
11th May 20057:00 amRNSLaunch in Japan
10th May 20057:00 amRNSNotice of Results
15th Apr 200511:59 amRNSStatement re. Press Comment
7th Apr 20057:00 amRNSre: Contracts
23rd Mar 200511:52 amRNSDirector Shareholding
23rd Mar 20057:00 amRNSMarchpole Update
21st Mar 20051:45 pmRNSBoateng Proceedings
24th Feb 20057:04 amRNSDirector Shareholding
24th Feb 20057:00 amRNSAgreement re Ungaro
22nd Feb 20057:00 amRNSDirector Shareholding
7th Feb 20051:52 pmRNSHolding(s) in Company
7th Feb 20057:00 amRNSHolding(s) in Company
1st Feb 20055:18 pmRNSDirector Shareholding
28th Jan 20052:21 pmRNSDirectorate Change
10th Jan 20057:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.